-+ 0.00%
-+ 0.00%
-+ 0.00%

Rein Therapeutics prices USD 50 million follow-on common stock offering at USD 1 share

PUBT·05/01/2026 00:02:11
Listen to the news
Rein Therapeutics prices USD 50 million follow-on common stock offering at USD 1 share
  • Rein Therapeutics priced an underwritten public offering of 50 million common shares at USD 1 per share.
  • Gross proceeds expected at USD 50 million.
  • Underwriters hold a 45-day option to buy up to 7,500,000 additional shares to cover over-allotments.
  • Offering expected to close on May 4, 2026.
  • Net proceeds earmarked to fund Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis through completion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.